ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Marla C. Dubinsky  1     Geert R. D'Haens  2     William J. Sandborn  3     Julian Panés  4     Chinyu Su  5     Nervin Lawendy  5     Irina Lazariciu  6     Sean Gardiner     Rajiv Mundayat     nicole kulisek     Irene Modesto     Siew C. Ng     Joana Torres    
1 Icahn School of Medicine at Mount Sinai,New York,United States
2 Amsterdam University Medical Centres,Amsterdam,Netherlands
3 University of California San Diego,La Jolla,United States
4 Hospital Clínic de Barcelona, IDIBAPS, CIBERehd,Barcelona,Spain
5 Pfizer Inc,Collegeville,United States
6 Pfizer In

Session
IBD (Posters)

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing